High Efficacy Of AbbVie’s Three-Drug Hep C Combo Holds Up In Cirrhotic Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
High cure rates in difficult-to-treat cirrhotic patients with genotype 1 hepatitis C reported at the European Association for the Study of the Liver annual meeting, as the company prepares to file for approval in the U.S and Europe this quarter.